LENSAR Q3 2022 revenue down 6% to $7.7M; net loss narrows to $4.0M; launches ALLY system

LENSAR, Inc.

2022-Q3 EPS reported -$1.73 revenue$25,126,000

Revenue $7.7M, down 6% YoY; U.S. procedure volume up 9%, offset by South Korean reimbursement challenges.
Net loss of $4.0M (-$0.39 per share) improved from $6.2M loss (-$0.65) in Q3 2021; Adjusted EBITDA -$1.6M.
Launched ALLY Adaptive Cataract Treatment System in the U.S. in August 2022; first installations with positive surgeon feedback.
R&D expenses dropped 50% to $1.6M as ALLY development costs capitalized after June 2022 clearance.
Approximately 88% of revenue from recurring sources; worldwide procedure volume 28,453 in Q3.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

LENSAR, Inc. reported the quarter ended September 30, 2022 results: revenue $7.7 million, net income $4.0 million, or ($0.39) per share.

Period: the quarter ended September 30, 2022
Revenue: $7.7 million
Net income: $4.0 million, or ($0.39) per share
Result: reported results

Exact text from the filing

with 2.5 - 3 minutes when using prior generation and competitive technologies.” Third Quarter 2022 Financial Results Total revenue for the quarter ended September 30, 2022 was $7.7 million, a decrease of $0.5 million, or 6%, compared to total revenue of $8.3 million for the quarter ended September 30, 2021. The decrease in third quarter 2022 revenue was associated

View on SEC.gov

Browse all earnings releases →

LENSAR, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023520

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.